Tonix Pharmaceuticals Holding Management
Management criteria checks 3/4
Tonix Pharmaceuticals Holding's CEO is Seth Lederman, appointed in Oct 2011, has a tenure of 12.58 years. total yearly compensation is $2.05M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $788.59. The average tenure of the management team and the board of directors is 4.3 years and 5.7 years respectively.
Key information
Seth Lederman
Chief executive officer
US$2.1m
Total compensation
CEO salary percentage | 32.9% |
CEO tenure | 12.6yrs |
CEO ownership | 0.005% |
Management average tenure | 4.3yrs |
Board average tenure | 5.7yrs |
Recent management updates
Recent updates
Tonix stock rises on FDA nod to start trial of TNX-601 for depression
Oct 03Tonix Pharmaceuticals GAAP EPS of -$1.22 beats by $0.23
Aug 08Tonix announces partnership to study monkeypox vaccine in 1H 2023
Jul 28Tonix Pharma to develop extended-release form of depression therapy
Jul 11Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?
Jun 21CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$675k | -US$117m |
Sep 30 2023 | n/a | n/a | -US$123m |
Jun 30 2023 | n/a | n/a | -US$124m |
Mar 31 2023 | n/a | n/a | -US$123m |
Dec 31 2022 | US$5m | US$675k | -US$117m |
Sep 30 2022 | n/a | n/a | -US$112m |
Jun 30 2022 | n/a | n/a | -US$102m |
Mar 31 2022 | n/a | n/a | -US$98m |
Dec 31 2021 | US$8m | US$675k | -US$92m |
Sep 30 2021 | n/a | n/a | -US$80m |
Jun 30 2021 | n/a | n/a | -US$73m |
Mar 31 2021 | n/a | n/a | -US$64m |
Dec 31 2020 | US$4m | US$614k | -US$52m |
Sep 30 2020 | n/a | n/a | -US$46m |
Jun 30 2020 | n/a | n/a | -US$42m |
Mar 31 2020 | n/a | n/a | -US$34m |
Dec 31 2019 | US$1m | US$585k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$31m |
Jun 30 2019 | n/a | n/a | -US$28m |
Mar 31 2019 | n/a | n/a | -US$29m |
Dec 31 2018 | US$1m | US$473k | -US$29m |
Sep 30 2018 | n/a | n/a | -US$24m |
Jun 30 2018 | n/a | n/a | -US$24m |
Mar 31 2018 | n/a | n/a | -US$23m |
Dec 31 2017 | US$576k | US$473k | -US$21m |
Compensation vs Market: Seth's total compensation ($USD2.05M) is above average for companies of similar size in the US market ($USD661.60K).
Compensation vs Earnings: Seth's compensation has been consistent with company performance over the past year.
CEO
Seth Lederman (65 yo)
12.6yrs
Tenure
US$2,050,065
Compensation
Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 12.6yrs | US$2.05m | 0.0046% $ 788.6 | |
CFO & Treasurer | 8.3yrs | US$904.91k | 0.00010% $ 17.0 | |
Chief Operating Officer | 8.3yrs | US$928.60k | 0% $ 0 | |
Chief Medical Officer & Secretary | 7.2yrs | US$952.00k | 0.00052% $ 88.2 | |
Executive Vice President of Translational Medicine | 4yrs | no data | no data | |
Executive Vice President of Product Development | no data | no data | no data | |
Executive Vice President of Experimental Chemistry | 4.3yrs | no data | no data | |
Executive Vice President of Infectious Disease Research & Development | 1.8yrs | no data | no data | |
Executive Vice President of Medical | 1.3yrs | no data | no data | |
Executive Vice President of Commercial Operations | less than a year | no data | no data |
4.3yrs
Average Tenure
57yo
Average Age
Experienced Management: TNXP's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 12.6yrs | US$2.05m | 0.0046% $ 788.6 | |
Independent Director | 5.7yrs | US$82.48k | 0.000030% $ 5.1 | |
Independent Director | 1.2yrs | US$113.05k | 0% $ 0 | |
Independent Director | 6.3yrs | US$82.48k | 0% $ 0 | |
Independent Director | 6.7yrs | US$82.48k | 0.000030% $ 5.1 | |
Independent Director | 3.9yrs | US$82.48k | 0.000050% $ 8.5 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Lead Director | 5.3yrs | US$102.48k | 0.000050% $ 8.5 | |
Member of Scientific Advisory Board | 12.9yrs | no data | no data | |
Independent Director | 2.8yrs | US$82.48k | 0% $ 0 |
5.7yrs
Average Tenure
65.5yo
Average Age
Experienced Board: TNXP's board of directors are considered experienced (5.7 years average tenure).